Fluticasone furoate plus vilanterol in patients with moderate persistent asthma: a cost-utility analysis

References

• Vaessen-Verberne AAPH, van den Berg NJ, van Nierop JC, Brackel HJL, Gerrits GPJM, Hop WCJ, Duiverman EJ. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med. 2010;182(10):1221–1227. doi:10.1164/rccm.201002-0193OC.
   PubMed Web of Science ®Google Scholar
• Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017;377(10):965–976. doi:10.1056/NEJMra1608969.
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol. 2012;129(5):1229–1235. doi:10.1016/j.jaci.2012.01.039.
   PubMed Web of Science ®Google Scholar
• Jefferson Antonio B, Patino DG, Lopez Moreno M. Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia. Expert Rev Pharmacoecon Outcomes Res. 2021:1–7. doi:10.1080/14737167.2021.1945445.
   Web of Science ®Google Scholar
• Jefferson Antonio B, Patino DG, Cossio-Giraldo YE. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma. J Asthma. 2021:1–8. doi:10.1080/02770903.2021.1984527.
   PubMed Web of Science ®Google Scholar
• Buendia JA, Patino DG, Feliciano-Alfonso JE. Cost-utility of azithromycin in patients with severe asthma. J Asthma. 2021:1–8. doi:10.1080/02770903.2021.1980586.
   PubMed Web of Science ®Google Scholar
• Nurmagambetov T, Kuwahara R, Garbe P. The economic burden of asthma in the United States, 2008–2013. Ann Am Thorac Soc. 2018;15(3):348–356. doi:10.1513/AnnalsATS.201703-259OC.
   PubMed Web of Science ®Google Scholar
• Parimi M, Svedsater H, Ann Q, Gokhale M, Gray CM, Hinds D, Nixon M, Boxall N. Persistence and adherence to ICS/LABA drugs in UK patients with asthma: a retrospective new-user cohort study. Adv Ther. 2020;37(6):2916–2931. doi:10.1007/s12325-020-01344-8.
   PubMed Web of Science ®Google Scholar
• Asthma GIf. Global strategy for ashtma management and prevention 2021. [06/05/2021]. https://ginasthma.org/.
   Google Scholar
• Jacques L, Bakerly ND, New JP, Svedsater H, Lay-Flurrie J, Leather DA. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study. J Asthma. 2019;56(7):748–757. doi:10.1080/02770903.2018.1490751.
   PubMed Web of Science ®Google Scholar
• Sánchez J, Morales E, Santamaria L-C, Acevedo A-M, Calle A, Olivares M, Gomez C, Amaya D, Cardona R. IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma. World Allergy Organ J. 2021;14(3):100520. doi:10.1016/j.waojou.2021.100520.
   PubMed Web of Science ®Google Scholar
• Pichon-Riviere A, Augustovski F, Garcia Marti S, Alfie V, Sampietro-Colom L. The link between health technology assessment and decision making for the allocation of health resources in Latin America. Int J Technol Assess Health Care. 2020;36(2):173–178. doi:10.1017/S0266462320000033.
   PubMed Web of Science ®Google Scholar
• Buendia JA, Rodriguez-Martinez CE, Sossa-Briceno MP. Cost-utility of tiotropium for children with severe asthma in patients aged 1-5 years. Pediatr Allergy Immunol. 2021;32(8):1866–1868.
   PubMed Web of Science ®Google Scholar
• Salud. IdETe. Manual metodológico para la elaboración de evaluaciones de efectividad, seguridad y validez diagnóstica de tecnologías en salud. 2014.
   Google Scholar
• Ministerio de salud C. Sistema de Informacion de Precios de Medicamentos (SISMED) 2021. [03/07/2121]. www.sispro.gov.co/central-prestadores-de-servicios/Pages/SISMED-Sistema-de-Informacion-de-Precios-de-Medicamentos.aspx.
   Google Scholar
• Florez-Tanus A, Parra D, Zakzuk J, Caraballo L, Alvis-Guzman N. Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis. World Allergy Organ J. 2018;11(1):26. doi:10.1186/s40413-018-0205-4.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Bereza BG, Nielsen TA, Hemels ME. Utilities for asthma and COPD according to category of severity: a comprehensive literature review. J Med Econ. 2015;18(7):550–563. doi:10.3111/13696998.2015.1025793.
   PubMed Web of Science ®Google Scholar
• Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S, Boulet L-P, Naya IP, Hultquist C. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin. 2004;20(9):1403–1418. doi:10.1185/030079904X2051.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007;16(1):22–27. doi:10.3132/pcrj.2007.00002.
   PubMedGoogle Scholar
• Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 3-Estimating probabilities and utilities. Med Decis Making. 1997;17(2):136–141. doi:10.1177/0272989X9701700203.
   PubMed Web of Science ®Google Scholar
• (DANE) DNdE. Archivo nacional de datos 2019. https://sitios.dane.gov.co/anda-index/.
   Google Scholar
• Beltrán J, Ga Moraes F, Alfonso Cristancho R, Di Boscio V, Soares C. Características clínicas, gravedad y control del asma en Colombia: un análisis post hoc del estudio ASLA (Asthma control in Latin America). Rev Colomb Neumol. 2020;31(2).
   Google Scholar
• Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1–e5. doi:10.1016/j.jval.2013.02.010.
   PubMed Web of Science ®Google Scholar
• Vallejo-Aparicio LA, Molina J, Ojanguren I, Viejo Casas A, Huerta A, Svedsater H. Cost-consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma. Eur J Health Econ. 2020;21(1):7–17. doi:10.1007/s10198-019-01101-x.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Shiobara T, Arai R, Chibana K, Takemasa A. Real-life effectiveness of fluticasone furoate/vilanterol after switching from fluticasone/salmeterol or budesonide/formoterol therapy in patients with symptomatic asthma: relvar ellipta for Real Asthma Control Study (RERACS study). J Thorac Dis. 2020;12(5):1877–1883. doi:10.21037/jtd-19-3913.
   PubMed Web of Science ®Google Scholar
• Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63(10):1292–1300. doi:10.1111/j.1398-9995.2008.01750.x.
   PubMed Web of Science ®Google Scholar
• Slack RJ, Barrett VJ, Morrison VS, Sturton RG, Emmons AJ, Ford AJ, Knowles RG. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013;344(1):218–230. doi:10.1124/jpet.112.198481.
   PubMed Web of Science ®Google Scholar
• Carayanni V, Tsati E. Explanatory versus pragmatic trial-based economic evaluations: application to alternative therapies for burns. Expert Rev Pharmacoecon Outcomes Res. 2010;10(1):37–48. doi:10.1586/erp.09.75.
   PubMed Web of Science ®Google Scholar
• Makhani LA, Moran V, Sadique Z, Singh NS, Revill P, Roberts B. Examining the use of economic evaluations in health-related humanitarian programmes in low- and middle-income countries: a systematic review. Health Policy Plan. 2020;35(2):210–218. doi:10.1093/heapol/czz144.
   PubMed Web of Science ®Google Scholar